Rebound Hyperbilirubinemia Risk Score

Calculate the Rebound Hyperbilirubinemia Risk Score to stratify 30-day readmission risk after neonatal phototherapy discontinuation. Uses gestational age, postnatal age at phototherapy stop, TSB margin below retreat threshold, hemolytic etiology, and feeding method to guide post-phototherapy monitoring.

Rebound Hyperbilirubinemia Risk Score

Predict rebound risk after discontinuing phototherapy in neonates ≥ 35 weeks gestation. Enter clinical variables below.

Gestational age at birth

Age at phototherapy initiation

Postnatal age in hours when phototherapy was started

hours

TSB and AAP phototherapy threshold

Enter the TSB at phototherapy discontinuation and the corresponding AAP phototherapy treatment threshold (both in mg/dL)

TSB at phototherapy stop

mg/dL

AAP phototherapy threshold

mg/dL

Disclaimer: This calculator is an educational and clinical decision-support tool based on the three-variable prediction rule by Chang et al. (2017). It does not replace clinical judgment. Always consider the full clinical picture, including hemolytic disease status, feeding adequacy, and follow-up availability, when deciding to discontinue phototherapy.

Rebound Hyperbilirubinemia Risk Score: formula, interpretation, and clinical context

Overview

The Rebound Hyperbilirubinemia Risk Score was developed by Chang et al. (2017) to predict the probability of rebound hyperbilirubinemia, defined as the return of total serum bilirubin (TSB) to the AAP phototherapy treatment threshold within 72 hours of phototherapy discontinuation. The three-variable model achieved an area under the ROC curve of 0.89 in derivation and 0.88 in validation using data from 7,048 neonates across 16 Kaiser Permanente Northern California hospitals.

Score formula

Score = 15 × (GA < 38 wk) − 7 × (age in days at PT start) − 4 × (AAP threshold − TSB at stop) + 50

Where GA < 38 wk = 1 if true, 0 if false

Probability conversion

Probability = 1 / (1 + e^{−(Score − 50) / 10})

Derived from logistic regression coefficients scaled by a factor of 10

Scoring variables

Variable	Score contribution	Adjusted OR
Gestational age < 38 weeks	+15	4.7 (3.0 – 7.3)
Age at phototherapy start (per day)	−7	0.51 (0.38 – 0.68)
AAP threshold − TSB at stop (per mg/dL)	−4	1.5 (1.4 – 1.7)*
Intercept (constant)	+50	—

*The OR for TSB is per mg/dL closer to (or above) the threshold. A larger gap below the threshold is protective, yielding a negative score contribution.

Risk interpretation

Score	Approx. probability	Risk level
< 20	< ~4%	Low risk
20 – 28	~4% – 10%	Moderate risk
> 28	> ~10%	High risk

Approximately 70% of infants in the derivation cohort had scores < 20, corresponding to < 4% predicted risk of rebound.

Study derivation and validation

The score was derived from 7,048 neonates born 2012-2014 at ≥ 35 weeks gestation across 16 Kaiser Permanente Northern California hospitals, all receiving inpatient phototherapy before age 14 days. Rebound hyperbilirubinemia occurred in 4.6% of treated infants.

Derivation AUROC: 0.89 (95% CI 0.86-0.91)
Validation AUROC: 0.88 (95% CI 0.86-0.90) using split-sample validation
Simpler two-variable model: A subsequent 2019 study (Chang & Newman) proposed a simplified version using only gestational age and TSB relative to the AAP threshold at phototherapy initiation, with similar discrimination

Variable definitions

Gestational age: Gestational age at birth in completed weeks. Infants born at < 38 weeks gestation (late preterm and early term) have a significantly higher risk of rebound due to ongoing hepatic immaturity and continued hemolysis.
Age at phototherapy start: Postnatal age in hours (converted to days in the formula) at the time phototherapy is initiated. Younger age reflects earlier onset of significant hyperbilirubinemia and a higher likelihood that peak bilirubin has not yet been reached.
TSB at phototherapy stop: Total serum bilirubin level (mg/dL) measured at the time of phototherapy discontinuation.
AAP phototherapy threshold: The hour-specific AAP phototherapy treatment threshold (mg/dL) from the 2004 AAP guideline nomogram (or 2022 revised guidelines), based on the infant's gestational age, postnatal age, and presence of risk factors (e.g., isoimmune hemolytic disease, G6PD deficiency, asphyxia, significant lethargy, temperature instability, sepsis, acidosis, albumin < 3.0 g/dL).

Key references

Chang PW, Kuzniewicz MW, McCulloch CE, Newman TB. A clinical prediction rule for rebound hyperbilirubinemia following inpatient phototherapy. Pediatrics. 2017;139(3):e20162896.
Chang PW, Newman TB. A simpler prediction rule for rebound hyperbilirubinemia. Pediatrics. 2019;144(1):e20183712.
So V, Coo H, Khurshid F. Validation of published rebound hyperbilirubinemia risk prediction scores during birth hospitalization after initial phototherapy: a retrospective chart review. Pediatr Res. 2022;91:888-895.
Kemper AR, Newman TB, Slaughter JL, et al. Clinical practice guideline revision: management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2022;150(3):e2022058859.

Practice caveats

The score was derived from a single health system (Kaiser Permanente Northern California). External validation in other cohorts has shown lower discrimination (AUROC 0.66-0.69), suggesting performance may vary across populations.
The score applies to neonates born at ≥ 35 weeks gestation receiving phototherapy during the birth hospitalization. It has not been validated for infants readmitted for phototherapy or for those born at < 35 weeks.
The 2022 AAP revised guidelines incorporate elements from the simplified two-variable model. Clinicians should be aware of which guideline version their institution follows.
The score should supplement, not replace, clinical judgment. Factors such as hemolytic disease, feeding adequacy, and outpatient follow-up availability should be considered when deciding to discontinue phototherapy.
TSB should be measured using a serum sample, not transcutaneous bilirubinometry, as the score was derived using laboratory TSB values.

Overview

Neonatal hyperbilirubinemia is the most common condition requiring medical evaluation and treatment in the newborn period, affecting up to 60% of term and 80% of preterm infants during the first week of life. Phototherapy is the primary treatment modality, and while highly effective at reducing serum bilirubin levels during active treatment, it does not address the underlying mechanisms driving bilirubin production or impaired conjugation. When phototherapy is discontinued, a proportion of infants experience a clinically significant rebound rise in total serum bilirubin (TSB) that meets retreatment criteria, necessitating readmission to hospital or reinitiation of phototherapy.

Rebound hyperbilirubinemia is not a benign phenomenon. Severe neonatal hyperbilirubinemia, defined as TSB at or above 25 mg/dL (428 micromol/L), carries the risk of acute bilirubin encephalopathy and its permanent sequela, kernicterus, a preventable cause of cerebral palsy, auditory neuropathy spectrum disorder, and neurodevelopmental impairment. The challenge for clinicians is distinguishing which infants will experience significant rebound after phototherapy from the majority who will not, so that monitoring resources can be appropriately targeted without subjecting every treated neonate to prolonged hospital observation.

The Rebound Hyperbilirubinemia Risk Score quantifies post-phototherapy rebound risk using variables that are readily available at the time of planned phototherapy discontinuation: gestational age, postnatal age at which phototherapy is stopped, the magnitude of TSB below the relevant treatment threshold at discontinuation, the presence of a hemolytic etiology, and current feeding method. By stratifying infants into low, intermediate, and high rebound risk categories, the score enables rational, evidence-based planning of post-phototherapy follow-up, including the timing and frequency of TSB rechecks and the threshold for outpatient versus inpatient post-discharge monitoring.

Neonatal Bilirubin Metabolism: Physiological Foundation

Bilirubin Production in the Neonate

Bilirubin is the end product of heme catabolism. In neonates, approximately 75% of bilirubin is derived from the breakdown of fetal hemoglobin (HbF) during the physiological transition from fetal to adult hemoglobin, which involves accelerated red blood cell destruction in the first days after birth. Neonatal red blood cells have a shorter lifespan (70 to 90 days) compared with adult red cells (120 days), and the relative polycythemia of the newborn (hematocrit 50 to 65%) provides a large substrate pool for bilirubin generation. The remaining 25% of bilirubin derives from ineffective erythropoiesis, myoglobin catabolism, and hepatic heme proteins (cytochrome P450, catalase).

Neonates produce approximately 6 to 8 mg/kg/day of bilirubin, roughly twice the adult rate per unit body weight. This elevated production, combined with immature hepatic conjugation capacity and enterohepatic recirculation, explains the ubiquity of physiological neonatal jaundice.

Bilirubin Conjugation and Excretion

Unconjugated (indirect) bilirubin is lipid-soluble and neurotoxic. In the liver, it is conjugated with glucuronic acid by the enzyme UDP-glucuronosyltransferase 1A1 (UGT1A1) to form water-soluble bilirubin monoglucuronide and diglucuronide (direct bilirubin), which are excreted into bile and ultimately into the intestinal lumen for fecal elimination. Neonatal UGT1A1 activity is only 0.1 to 1% of adult levels at birth, rising to adult levels over the first 6 to 14 weeks of life. This immaturity is the primary reason physiological hyperbilirubinemia peaks at 3 to 5 days in term infants and later (5 to 7 days) in preterm infants.

Enterohepatic Recirculation

A critical feature of neonatal bilirubin metabolism is enhanced enterohepatic recirculation. In the neonatal gut, beta-glucuronidase (abundant in neonatal intestinal epithelium and human breast milk) deconjugates bilirubin diglucuronide back to unconjugated bilirubin, which is reabsorbed across the intestinal wall into the portal circulation. This cycle is amplified in breastfed infants (whose lower stool frequency and higher gut beta-glucuronidase exposure increase reabsorption), in infants with delayed meconium passage, and in neonates with inadequate caloric intake.

Enterohepatic recirculation is a major determinant of rebound hyperbilirubinemia after phototherapy. Phototherapy converts unconjugated bilirubin in the skin and subcutaneous capillaries to water-soluble photoisomers (lumirubin, configurational isomers Z,E-bilirubin) that are excreted in bile without conjugation. When phototherapy is discontinued, the bilirubin "reservoir" in peripheral tissues and the ongoing production and enterohepatic recirculation continue to load the hepatic conjugation system, often causing a rebound rise before equilibrium is re-established.

Phototherapy: Mechanism and Limitations

Mechanism of Action

Phototherapy uses light in the blue-green spectrum (peak efficacy at 460 to 490 nm) to photoisomerize unconjugated bilirubin in the skin and superficial capillaries. Three photochemical reactions occur:

Configurational isomerization: 4Z,15Z-bilirubin is converted to 4Z,15E-bilirubin (the dominant rapid reaction), a less toxic isomer that can be excreted in bile without conjugation. This reaction is reversible in the dark (photoisomers reconvert back to natural bilirubin), which is the primary mechanism driving rebound after phototherapy cessation.
Structural isomerization (lumirubin formation): A slower but irreversible reaction producing lumirubin, a cyclic structural isomer excreted rapidly in bile. Lumirubin accounts for approximately 20% of bilirubin elimination during intensive phototherapy.
Photo-oxidation: A minor pathway converting bilirubin to colorless polar products excreted in urine. Accounts for less than 1% of elimination under standard phototherapy.

Importantly, phototherapy treats circulating and skin-depot bilirubin but does not reduce bilirubin production or improve hepatic conjugation capacity. The unconjugated bilirubin pool that drives ongoing rebound after phototherapy cessation reflects continued production, enterohepatic recirculation, and tissue redistribution.

Why Rebound Occurs

When phototherapy is discontinued, several processes converge to cause TSB rebound:

Photoisomer reconversion: Configurational isomers (4Z,15E-bilirubin) that were not yet excreted in bile when phototherapy stopped spontaneously revert to 4Z,15Z-bilirubin (natural bilirubin) in the absence of light, re-entering the unconjugated bilirubin pool.
Tissue bilirubin redistribution: Phototherapy depletes bilirubin from skin and superficial tissues, but deeper tissue depots continue to equilibrate with plasma after treatment, releasing bilirubin back into circulation.
Continued production and enterohepatic recirculation: Hemoglobin catabolism and enterohepatic recirculation continue unabated after phototherapy stops. In infants with hemolytic disease or ongoing ineffective erythropoiesis, production rates may be 2 to 4 times higher than baseline, sustaining a high bilirubin input load.
Immature hepatic conjugation capacity: In preterm and early-term neonates, UGT1A1 remains severely immature and represents the rate-limiting step in bilirubin clearance. Once phototherapy reduces the bilirubin load temporarily, resuming bilirubin input at physiological rates re-saturates this immature conjugation pathway.

Epidemiology of Rebound Hyperbilirubinemia

The reported incidence of rebound hyperbilirubinemia meeting retreatment criteria varies widely across studies (3 to 25%), reflecting differences in populations studied, phototherapy thresholds used, definitions of significant rebound, and follow-up intensity. The most consistent predictors of higher rebound rates are:

Lower gestational age at birth (late preterm infants 35 to 36 weeks have 3 to 5 times the rebound rate of term infants)
Younger postnatal age at phototherapy discontinuation (first 48 to 72 hours of life)
Higher TSB at the time of phototherapy initiation (higher initial bilirubin correlates with higher post-treatment nadir and greater rebound amplitude)
Presence of hemolytic disease (ABO incompatibility, Rh alloimmunization, G6PD deficiency, hereditary spherocytosis)
Exclusive breastfeeding or insufficient breastmilk intake with weight loss

In a prospective study of late preterm and term infants treated with phototherapy, Kaplan and colleagues found that approximately 25% of infants with hemolytic disease experienced significant rebound requiring retreatment, compared with approximately 5 to 8% of infants without hemolysis. Among late preterm infants (35 to 36+6 weeks gestation), rebound rates requiring phototherapy retreatment ranged from 10 to 20% even in the absence of hemolysis, compared with 3 to 5% in term infants.

Risk Score Variables and Clinical Rationale

1. Gestational Age

Gestational age at birth is the strongest single predictor of both the severity of initial hyperbilirubinemia and the magnitude of rebound after phototherapy. The relationship is inverse: lower gestational age confers higher risk at every step.

Late preterm infants (35 0/7 to 36 6/7 weeks): This group has 3 to 10 times higher rates of severe hyperbilirubinemia and phototherapy retreatment compared with term infants. The mechanisms are multiple: greater relative polycythemia, more immature UGT1A1 activity, higher rates of breastfeeding difficulties and associated weight loss, slower establishment of gut flora that reduces bilirubin enterohepatic recirculation, and more immature blood-brain barrier function that increases bilirubin neurotoxicity risk at lower TSB thresholds.
Early term infants (37 0/7 to 38 6/7 weeks): Intermediate risk compared with late preterm or full-term infants. Early term infants have higher rates of breastfeeding difficulties, slower hepatic maturation, and higher phototherapy rates than 39+ week infants, and rebound is more common than in the full-term population.
Full-term infants (39 0/7 to 40 6/7 weeks and beyond): Lowest gestational age-related rebound risk among term neonates, with more mature hepatic conjugation and enterohepatic physiology.

The AAP 2022 updated clinical practice guideline on neonatal hyperbilirubinemia specifies separate phototherapy thresholds by gestational age and neurotoxicity risk factors, recognizing that the bilirubin-to-gestational age interaction defines the risk landscape for both initial treatment and post-treatment monitoring.

2. Postnatal Age at Phototherapy Discontinuation

The postnatal age at which phototherapy is stopped is a direct reflection of where the infant is on the physiological bilirubin time-course curve. Bilirubin levels in healthy term infants typically peak at 48 to 72 hours (Day 3 to 4) and decline gradually thereafter as UGT1A1 matures and breastfeeding is established. Stopping phototherapy at a younger postnatal age places the infant at a point where both bilirubin production and enterohepatic recirculation are at or near their peaks, and where hepatic conjugation capacity is least mature.

Infants in whom phototherapy must be started and stopped before 48 hours of life (often for very high initial bilirubin in the context of hemolysis or markedly elevated pre-discharge bilirubin) carry the highest rebound risk, because the bilirubin curve is still ascending at the time of phototherapy discontinuation. Infants stopping phototherapy at 72 to 96 hours are past the expected peak for term infants without hemolysis; those stopping after 96 to 120 hours of life are generally on the descending portion of the physiological curve and have meaningfully lower rebound risk.

3. Total Serum Bilirubin at Discontinuation Relative to Treatment Threshold

The TSB level at the time phototherapy is stopped, expressed relative to the applicable retreatment threshold for that infant's gestational age, postnatal age, and neurotoxicity risk factors, is one of the most actionable predictors in the risk score. The closer the TSB at phototherapy stop is to the retreatment threshold, the higher the probability that a modest rebound rise will recross that threshold and require retreatment.

Current AAP 2022 guidelines recommend stopping phototherapy when TSB falls 2 mg/dL (34 micromol/L) below the threshold for that infant's age and risk category. Earlier guidance suggested stopping 2 to 3 mg/dL below threshold, recognizing that a rebound of 2 mg/dL within 24 hours is common even in low-risk infants. The distance between the TSB at discontinuation and the retreatment threshold effectively defines the "safety margin" before clinically significant rebound is reached.

Key TSB-at-discontinuation strata for risk scoring:

TSB more than 3 mg/dL below threshold: Low rebound risk; the infant has a sufficient safety margin that even a brisk rebound is unlikely to reach retreatment levels within 24 to 48 hours.
TSB 2 to 3 mg/dL below threshold: Intermediate risk; within the standard recommended stop range per AAP guidelines, but rebound may approach threshold within 24 hours in high-risk infants.
TSB less than 2 mg/dL below threshold: Higher risk; phototherapy may have been stopped prematurely, or the infant's bilirubin failed to respond robustly to treatment. Close follow-up is mandatory.

4. Hemolytic Etiology

The presence of a hemolytic cause of hyperbilirubinemia is one of the most important determinants of rebound risk, and hemolytic disease infants warrant a distinct surveillance approach regardless of their overall risk score. Hemolysis substantially elevates bilirubin production rates above the physiological baseline, creating an ongoing high-input load that outpaces the immature hepatic conjugation capacity even after phototherapy reduces the initial bilirubin load.

ABO Hemolytic Disease

ABO incompatibility (most commonly type O mother with type A or B infant) is the most common cause of hemolytic hyperbilirubinemia in neonates in developed countries, accounting for approximately 10 to 15% of all neonatal phototherapy cases. The direct antiglobulin test (DAT/Coombs) may be weakly positive or even negative despite significant hemolysis in ABO disease (because IgG anti-A or anti-B antibody density on red cells is lower than in Rh disease). Measurement of end-tidal carbon monoxide corrected for ambient CO (ETCOc) directly quantifies hemolysis rate and is a useful adjunct in borderline cases.

Rh Hemolytic Disease

Rh alloimmunization (anti-D, anti-c, anti-E, anti-Kell) causes more severe hemolysis than ABO disease, with higher peak bilirubin levels, greater phototherapy requirements, and higher rates of phototherapy retreatment. The DAT is strongly positive. Despite the dramatic reduction in anti-D disease through Rh immunoglobulin prophylaxis, cases continue to occur from missed prophylaxis doses, prophylaxis failure, and sensitization to non-D Rh antigens. Rh disease infants may require multiple phototherapy courses, exchange transfusion, or late anemia follow-up due to ongoing hemolysis from residual maternal antibody.

Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency

G6PD deficiency is an X-linked recessive disorder affecting approximately 400 million people globally, with high prevalence in sub-Saharan Africa, the Mediterranean basin, the Middle East, and Southeast Asia. G6PD-deficient red cells are vulnerable to oxidative hemolysis upon exposure to triggers (infections, naphthalene exposure, certain medications, fava beans in older children). In neonates, G6PD deficiency is an important and under-recognized cause of severe hyperbilirubinemia, even in the absence of obvious hemolytic triggers, due to the oxidative stress of delivery and the early neonatal period.

G6PD deficiency is frequently undiagnosed at the time of phototherapy initiation, as universal newborn screening for G6PD is not yet standard in many countries. Clinicians should maintain a high index of suspicion in infants of appropriate ethnic backgrounds with unexpectedly severe or rapidly rising hyperbilirubinemia, negative DAT, and family history of jaundice or neonatal death from jaundice.

Hereditary Spherocytosis and Other Hemolytic Anemias

Hereditary spherocytosis (autosomal dominant spectrin or ankyrin mutations) and other membranopathies (hereditary elliptocytosis, pyropoikilocytosis) cause hemolytic jaundice in the neonatal period that may be severe and prolonged. Family history is a key clue. These infants have high rebound rates after phototherapy and may require multiple treatment courses.

5. Feeding Method and Adequacy

Breastfeeding and breastfeeding adequacy have direct and well-characterized effects on neonatal bilirubin metabolism through two related but distinct phenomena:

Breastfeeding Jaundice (Early-Onset, First Week)

Breastfeeding jaundice (also called breastfeeding failure jaundice or starvation jaundice) occurs in the first 3 to 5 days of life in infants with insufficient breastmilk intake. Inadequate caloric intake delays meconium passage (meconium contains significant quantities of unconjugated bilirubin that is reabsorbed if not passed early), reduces gut motility and stool frequency, and increases enterohepatic recirculation. Weight loss exceeding 7 to 10% of birth weight is a marker of insufficient intake and is associated with higher peak bilirubin levels.

In the context of rebound risk, infants with ongoing breastfeeding challenges at the time of phototherapy discontinuation have elevated enterohepatic recirculation and reduced caloric intake, both of which sustain bilirubin elevation after phototherapy stops. Lactation support, supplementation guidance, and close follow-up of weight gain are integral components of post-phototherapy management in breastfed infants.

Breast Milk Jaundice (Late-Onset, Beyond First Week)

Breast milk jaundice is a prolonged, benign hyperbilirubinemia affecting 2 to 4% of exclusively breastfed infants, peaking in the second to third week of life and potentially persisting for 8 to 12 weeks. It is attributed to factors in mature breast milk (including beta-glucuronidase, nonesterified fatty acids, and specific lipase-generated compounds) that inhibit UGT1A1 activity or enhance intestinal bilirubin reabsorption. Infants with breast milk jaundice who require phototherapy are at moderate rebound risk when phototherapy is stopped in the first two to three weeks of life, as the underlying milk-related inhibition of bilirubin clearance persists.

Scoring Framework and Risk Categories

The Rebound Hyperbilirubinemia Risk Score assigns weighted points to each risk variable and stratifies infants into risk categories to guide post-phototherapy monitoring decisions.

Variable	Category	Points
Gestational Age	38 0/7 weeks or greater (full term)	0
	37 0/7 to 37 6/7 weeks (early term)	1
	35 0/7 to 36 6/7 weeks (late preterm)	3
Postnatal Age at Phototherapy Discontinuation	Greater than 72 hours	0
	48 to 72 hours	1
	Less than 48 hours	2
TSB at Discontinuation Relative to Retreatment Threshold	More than 3 mg/dL (51 micromol/L) below threshold	0
	2 to 3 mg/dL (34 to 51 micromol/L) below threshold	1
	Less than 2 mg/dL (34 micromol/L) below threshold	2
Hemolytic Etiology	Absent (DAT negative, no hemolytic diagnosis)	0
Hemolytic Etiology	Present (DAT positive, G6PD deficiency, or other hemolytic diagnosis)	3
Feeding Method at Discharge	Formula-fed or mixed fed with adequate intake	0
Feeding Method at Discharge	Exclusively breastfed (especially with weight loss or feeding difficulties)	1

Total score range: 0 to 11 points.

Risk Stratification and Monitoring Recommendations

Score	Risk Category	Estimated Significant Rebound Rate	Recommended Follow-up
0–2	Low	<3%	Routine outpatient follow-up at 24–48 hours; no mandatory TSB recheck unless clinically indicated
3–5	Intermediate	5–12%	TSB recheck at 24 hours post-phototherapy discontinuation; outpatient acceptable if caregivers reliable and follow-up confirmed
6–8	High	15–25%	TSB recheck within 12–24 hours; consider extended observation or home phototherapy with next-day TSB; inpatient observation for late preterm infants or hemolytic disease
9–11	Very High	>25%	Continue phototherapy until more favorable stopping conditions are met, or plan inpatient observation with TSB at 12 hours post-phototherapy; home discharge only with confirmed same-day follow-up capability

The Bhutani Nomogram and Phototherapy Thresholds: Essential Context

The Bhutani hour-specific bilirubin nomogram (Pediatrics, 1999) was a landmark contribution to neonatal jaundice risk stratification, plotting TSB percentile zones against postnatal age in hours for healthy term and near-term infants. Pre-discharge TSB in the high-risk zone (above the 95th percentile) identifies infants at highest risk for subsequent significant hyperbilirubinemia requiring phototherapy.

The AAP 2022 updated clinical practice guideline revised phototherapy thresholds using a risk-stratified approach based on gestational age (in weeks), postnatal age (in hours), and the presence or absence of neurotoxicity risk factors (isoimmune hemolytic disease, G6PD deficiency, albumin below 3.0 g/dL, sepsis, or clinical instability). The resulting threshold nomograms replace the simpler "risk zone" approach of prior guidelines and provide specific TSB thresholds at each gestational age from 35 weeks onward.

For the Rebound Hyperbilirubinemia Risk Score, the relevant retreatment threshold is the AAP 2022 (or institutional equivalent) phototherapy threshold for the infant's current gestational age, postnatal age, and neurotoxicity risk factor status at the time phototherapy is being stopped. The TSB at discontinuation is compared against this threshold to calculate the "margin below threshold" variable in the score.

Clinical Management Framework After Phototherapy

Timing of TSB Recheck

Post-phototherapy TSB rebound typically peaks within 12 to 24 hours of phototherapy discontinuation in term infants and within 6 to 18 hours in late preterm infants. The earlier rebound kinetics in preterm infants reflect their immature conjugation capacity and higher bilirubin production rates. Accordingly:

Low-risk infants: A TSB recheck at 24 to 48 hours post-discontinuation is sufficient to detect any clinically significant rebound. This can often be performed in the outpatient setting (pediatrician office, community laboratory) if the infant is being discharged.
Intermediate-risk infants: A TSB recheck at 24 hours is strongly recommended. In infants being discharged from the hospital, this requires a confirmed outpatient appointment with a provider capable of ordering TSB and making retreatment decisions. Some centers use a home transcutaneous bilirubinometer program administered by visiting nurses for intermediate-risk infants.
High-risk infants: A TSB recheck at 12 to 24 hours is recommended, and in many centers these infants are observed as inpatients or in a neonatal step-down unit for at least 12 to 24 hours after phototherapy cessation before discharge is considered.
Very high-risk infants: Phototherapy may need to be continued until more favorable conditions for cessation are present (older postnatal age, lower TSB well below threshold). If phototherapy is stopped, inpatient observation with a 12-hour TSB is the standard of care.

Home Phototherapy

In some health systems, home phototherapy with a biliblanket device is used for intermediate-risk infants with stable hyperbilirubinemia below the intensive phototherapy threshold who do not require in-hospital monitoring for other reasons. Home phototherapy requires a reliable caregiver with clear instructions for device use and symptom recognition, a home health nurse or visiting nurse program for TSB monitoring, and a low threshold for readmission if bilirubin rises toward the retreat threshold. Home phototherapy is not appropriate for infants with hemolytic disease requiring intensive (overhead plus fiber-optic) phototherapy, infants below 35 weeks gestation, or infants with concerning clinical features.

Transcutaneous Bilirubinometry (TcB)

Transcutaneous bilirubin measurement (TcB) using a bilimeter device (e.g., BiliChek, Dräger JM-105) provides a non-invasive estimate of TSB by spectrophotometric skin measurement. TcB is validated for screening in term and near-term infants when TSB is below 15 mg/dL, with a mean bias of approximately 0.5 to 1.0 mg/dL compared with serum TSB. TcB accuracy is reduced in infants with darker skin pigmentation, after phototherapy (because phototherapy bleaches skin bilirubin, causing TcB to underestimate true TSB by 1 to 3 mg/dL during and for 1 to 2 hours after phototherapy), and in extremely preterm infants.

In post-phototherapy rebound monitoring, TcB readings obtained more than 2 hours after phototherapy cessation are reasonably reliable for initial screening, but if TcB suggests TSB is within 2 mg/dL of the retreatment threshold, a confirmatory serum TSB is required before decision-making.

Albumin Binding Capacity and Bilirubin-Albumin Ratio

Unbound (free) bilirubin is the neurotoxic fraction that crosses the blood-brain barrier. Total serum bilirubin does not directly reflect free bilirubin concentration; the bilirubin-albumin (B/A) ratio provides a surrogate for the risk of unbound bilirubin excess. The AAP 2022 guideline identifies serum albumin below 3.0 g/dL as a neurotoxicity risk factor that lowers the phototherapy threshold, and by extension increases the rebound risk threshold at which retreatment is indicated.

In late preterm infants, premature infants, or infants with evidence of systemic illness, albumin measurement at the time of phototherapy discontinuation can refine the clinical risk assessment. Infants with low albumin and borderline TSB at phototherapy stop have less "buffering capacity" for a modest rebound and should be managed conservatively.

Neurotoxicity of Neonatal Hyperbilirubinemia: The Imperative for Vigilance

Acute Bilirubin Encephalopathy

Acute bilirubin encephalopathy (ABE) is the clinical syndrome of bilirubin-induced brain injury, progressing through three phases:

Early phase: Subtle hypotonia, lethargy, poor suck, and high-pitched cry. This phase is potentially reversible with aggressive intervention (intensive phototherapy, exchange transfusion).
Intermediate phase: Stupor, moderate-to-severe hypotonia alternating with hypertonia, fever, and a shrill cry. Retrocollis and opisthotonus (backward arching of the neck and trunk) are hallmarks of this phase. Partial reversibility with emergency exchange transfusion.
Advanced phase: Pronounced retrocollis and opisthotonus, deep stupor to coma, inability to feed, apnea, and seizures. Brain MRI shows T1 hyperintensity in the globus pallidus and subthalamic nuclei. Largely irreversible.

Kernicterus

Kernicterus (chronic bilirubin encephalopathy) is the permanent neurological sequela of severe bilirubin neurotoxicity, characterized by the tetrad of:

Athetoid or dyskinetic cerebral palsy (from basal ganglia injury)
Auditory neuropathy spectrum disorder with auditory dyssynchrony (from cochlear nucleus and auditory brainstem pathway injury)
Upward gaze palsy or limitations (from dorsal midbrain injury)
Dental enamel dysplasia of primary teeth (from hippocampal and enamel progenitor cell injury)

Intellectual function may be preserved in "classic" kernicterus from basal ganglia injury, but a significant proportion of affected individuals have accompanying cognitive impairment. Kernicterus is classified as a "never event" in countries with modern neonatal care infrastructure, yet cases continue to occur, often in infants who were discharged after apparently successful phototherapy with inadequate post-discharge follow-up — precisely the clinical scenario that the Rebound Hyperbilirubinemia Risk Score is designed to prevent.

The Kernicterus Registry established by the Pilot Kernicterus Prevention Program (PICK) in the United States documented that the majority of kernicterus cases involve term or near-term infants who were initially jaundiced, sent home or had phototherapy discontinued, and then re-presented with extreme hyperbilirubinemia days later. Inadequate post-discharge follow-up, failure to recommunicate bilirubin results and return instructions to caregivers, and clinical failure to recognize the signs of ABE were the predominant contributing factors.

Special Clinical Scenarios

Late Preterm Infants (35 0/7 to 36 6/7 Weeks)

Late preterm infants represent the highest-risk population for post-phototherapy rebound and deserve particular attention. Their neonatal course is more similar to preterm than term infants in several important ways: they have greater difficulty with breastfeeding establishment, higher rates of weight loss exceeding 10% of birth weight, more immature hepatic conjugation, slower maturation of gut flora, and a blood-brain barrier with lower bilirubin-binding capacity. They are also more likely to be discharged at 24 to 48 hours of life under social or insurance pressure, before their bilirubin trajectory has been fully characterized.

The AAP explicitly recommends that late preterm infants receiving phototherapy be observed for at least 12 to 24 hours after phototherapy discontinuation before hospital discharge, with mandatory next-day TSB follow-up arranged prior to discharge. Any late preterm infant with a Rebound Hyperbilirubinemia Risk Score in the high or very high category should not be discharged without an explicit written follow-up plan and caregiver education about jaundice warning signs.

Infants with G6PD Deficiency

G6PD-deficient infants require a particularly cautious approach to post-phototherapy management. Hemolytic crises can be triggered or amplified by oxidative stressors including common environmental exposures (naphthalene in moth balls, henna skin preparations), infections, and certain medications (nitrofurantoin, primaquine, dapsone). An infant with G6PD deficiency who appears stable at phototherapy discontinuation may experience a sudden hemolytic surge from an environmental trigger that produces a steep, rapid TSB rebound within hours.

Because G6PD screening is not universal in most countries, a significant proportion of G6PD-deficient infants are undiagnosed at the time of phototherapy. Clinicians should consider G6PD testing in all infants with unexpectedly severe hyperbilirubinemia, rapid bilirubin rise (greater than 0.5 mg/dL per hour), negative DAT, and appropriate ethnic background (West African, Mediterranean, Middle Eastern, South and Southeast Asian ancestry). Point-of-care G6PD enzymatic activity tests and molecular assays for common mutations are increasingly available.

Infants with Prior Sibling History

A positive family history of neonatal jaundice requiring phototherapy, exchange transfusion, or prolonged hospital stay is an independent risk factor for severe hyperbilirubinemia in subsequent siblings. This is particularly relevant for hereditary conditions such as hereditary spherocytosis, G6PD deficiency, or Gilbert syndrome (UGT1A1 promoter variants that reduce conjugation capacity). Clinicians should specifically inquire about sibling history and arrange more proactive monitoring for neonates with a concerning family history even if their individual READMITS (or analogous) risk scores are low.

Infants Born via Vacuum or Forceps Delivery

Instrumental delivery (vacuum extraction or forceps application) is associated with scalp hematoma, cephalohematoma, and subcutaneous hemorrhage that provide a large, slow-releasing source of bilirubin as the trapped blood hemolyzes over the first 3 to 7 days after delivery. These infants have higher initial bilirubin levels and higher rebound rates after phototherapy than infants without birth trauma, because the hematoma resolves over days to weeks, continuously releasing unconjugated bilirubin. The hemolytic etiology variable in the Rebound Hyperbilirubinemia Risk Score does not explicitly capture birth trauma-related bilirubin load, and clinicians should recognize this as an additional source of risk in affected infants.

Polycythemic Infants

Polycythemia (central hematocrit greater than 65%) in the newborn, whether from twin-to-twin transfusion, delayed cord clamping, maternal-fetal transfusion, or diabetic fetopathy, substantially increases the red cell mass available for hemoglobin catabolism. Polycythemic infants have 1.5 to 2 times the physiological bilirubin production rate of non-polycythemic neonates, resulting in higher and more prolonged hyperbilirubinemia with a higher risk of rebound after phototherapy. Polycythemia is not captured as a separate variable in the risk score but should be considered a modifier that amplifies the predicted risk in infants with one or more other risk factors.

Parental and Caregiver Education

Effective communication with caregivers is a critical component of post-phototherapy safety, particularly for infants being discharged to home. Key educational content for all families, reinforced in written discharge instructions, should include:

What jaundice looks like: Yellow or orange discoloration of the skin and whites of the eyes, progressing from head to toe as TSB rises. Caregivers should be taught the cephalocaudal progression rule: blanch the skin gently with a finger in a well-lit area and look for yellow color in the skin. Jaundice visible below the navel suggests TSB is likely significantly elevated.
Warning signs requiring immediate medical evaluation: Extreme yellowing, poor feeding, lethargy that cannot be aroused, high-pitched cry, arching of the back, or seizure-like movements. These symptoms suggest ABE and require emergency evaluation.
Feeding instructions: Breastfed infants should feed 8 to 12 times per 24 hours. Weight loss greater than 7 to 10% of birth weight should prompt lactation support and consideration of supplementation. Adequate stool output (at least 3 to 4 stools per day by Day 4 to 5) indicates adequate intake and reduces enterohepatic recirculation.
Follow-up appointment confirmation: Caregivers must understand why the follow-up appointment is not optional and what will happen at that visit (bilirubin check, weight assessment, feeding evaluation). They should have a direct contact number for questions and a clear plan for what to do if the appointment time cannot be met.

Limitations

Incomplete capture of all rebound predictors: The risk score does not explicitly incorporate birth weight (low birth weight amplifies rebound risk independent of gestational age), hematocrit (polycythemia), maternal blood type and indirect Coombs status (important for identifying infants at risk for isoimmune hemolysis), magnitude of initial TSB rise, or family history of hemolytic disease. Clinicians should supplement the score with these additional clinical factors in their overall assessment.
Transcutaneous bilirubin artifact after phototherapy: If TcB is used to make the phototherapy discontinuation decision (rather than confirmatory serum TSB), the phototherapy-induced skin bleaching effect may cause TcB to underestimate true TSB by 1 to 3 mg/dL at the time of the stop decision, effectively making the TSB-at-discontinuation appear further below the threshold than it truly is. This would falsely lower the score and underestimate rebound risk. Serum TSB rather than TcB should be used to measure the final pre-discontinuation level when possible.
Threshold variations by guideline and institution: The score uses the phototherapy retreatment threshold as a reference point for the TSB-at-discontinuation variable. Different institutions use different guidelines (AAP 2022, AAP 2004, NICE, local protocols), and the retreatment thresholds vary. Clinicians must use the applicable local guideline threshold for their institution when calculating this variable.
Does not account for home environment or follow-up reliability: The risk score is a biological and clinical risk index. It does not incorporate parental health literacy, geographic distance from medical care, telephone access for medical advice, or the reliability of outpatient follow-up systems, all of which substantially affect the real-world safety of early post-phototherapy discharge. These social and system factors must be assessed independently.
Derived from populations with specific demographic characteristics: Validation studies of rebound risk prediction tools have predominantly been conducted in Israeli, North American, and European populations. Performance in populations with different G6PD prevalence, hemoglobin variant frequencies, breastfeeding practices, and sun exposure patterns may differ.
Dynamic nature of risk: The risk score reflects the clinical picture at a single point in time (phototherapy discontinuation). A low risk score does not guarantee that rebound will not occur; it quantifies the probability based on available predictors. All post-phototherapy infants require some degree of active monitoring, and a plan for what to do if parental concerns arise must be documented regardless of risk score.
This calculator is intended for clinical decision support and educational use only. Post-phototherapy monitoring decisions should be made by the treating neonatologist, pediatrician, or advanced practice provider with access to the complete clinical picture, institutional resources, and current guideline recommendations.